Current treatment options for vulvovaginal atrophy

References

• Calleja-AgiusJ, Brincat MP. Urogenital atrophy. Climacteric12(4), 279–285 (2009).
   PubMed Web of Science ®Google Scholar
• MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin. Proc.85(1), 87–94 (2010).
   PubMed Web of Science ®Google Scholar
• Lewis V. Undertreatment of menopausal symptoms and novel options for comprehensive management. Curr. Med. Res. Opin.25(11), 2689–2698 (2009).
   PubMed Web of Science ®Google Scholar
• Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas49(4), 292–303 (2004).
   PubMed Web of Science ®Google Scholar
• Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause15(4 Pt 1), 661–666 (2008).
   PubMed Web of Science ®Google Scholar
• SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Int. J. Gynaecol. Obstet.88(2), 222–228 (2005).
   PubMed Web of Science ®Google Scholar
• Hill K. The demography of menopause. Maturitas23(2), 113–127 (1996).
   PubMed Web of Science ®Google Scholar
• Rutanen EM, Heikkinen J, Halonen K et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause10(5), 433–439 (2003).
   PubMed Web of Science ®Google Scholar
• Meisels A. The maturation value. Acta Cytol.11(4), 249 (1967).
   PubMed Web of Science ®Google Scholar
• Hess R, Austin RM, Dillon S, Chang CC, Ness RB. Vaginal maturation index self-sample collection in mid-life women: acceptability and correlation with physician-collected samples. Menopause15(4 Pt 1), 726–729 (2008).
   PubMed Web of Science ®Google Scholar
• Greene JG. Constructing a standard climacteric scale. Maturitas29(1), 25–31 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas50(3), 209–221 (2005).
   PubMed Web of Science ®Google Scholar
• Hilditch JR, Lewis J, Peter A et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas24(3), 161–175 (1996).
   PubMed Web of Science ®Google Scholar
• Blatt MH, Wiesbader H, Kupperman HS. Vitamin E and climacteric syndrome; failure of effective control as measured by menopausal index. AMA Arch. Intern. Med.91(6), 792–799 (1953).
   PubMedGoogle Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric13(2), 132–140 (2010).
   PubMed Web of Science ®Google Scholar
• McGahuey CA, Gelenberg AJ, Laukes CA et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex Marital Ther.26(1), 25–40 (2000).
   PubMed Web of Science ®Google Scholar
• van Die MD, Teede HJ, Bone KM, Reece JE, Burger HG. Predictors of placebo response in a randomized, controlled trial of phytotherapy in menopause. Menopause16(4), 792–796 (2009).
   PubMed Web of Science ®Google Scholar
• Indhavivadhana S, Leerasiri P, Rattanachaiyanont M et al. Vaginal atrophy and sexual dysfunction in current users of systemic postmenopausal hormone therapy. J. Med. Assoc. Thai.93(6), 667–675 (2010).
   PubMedGoogle Scholar
• Mehta A, Bachmann G. Vulvovaginal complaints. Clin. Obstet. Gynecol.51(3), 549–555 (2008).
   PubMed Web of Science ®Google Scholar
• Barlow DH, Samsioe G, van Geelen JM. A study of European womens’ experience of the problems of urogenital ageing and its management. Maturitas27(3), 239–247 (1997).
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet. Gynecol.96(3), 351–358 (2000).
   PubMed Web of Science ®Google Scholar
• Le Donne M, Caruso C, Mancuso A et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch. Gynecol. Obstet. DOI: 10.1007/s00404-010-1545-7 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: a prevalence study. Int. Urogynecol. J. Pelvic Floor Dysfunct.12(2), 107–110 (2001).
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer Breast. Cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet350(9084), 1047–1059 (1997).
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol.85(2), 304–313 (1995).
   PubMed Web of Science ®Google Scholar
• Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J. Sex. Med.2(Suppl. 3), 154–165 (2005).
   PubMed Web of Science ®Google Scholar
• Ekin M, Yasar L, Savan K et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch. Gynecol. Obstet. DOI: 10.1007/s00404-010-1382-8 (2010) (Epub ahead of print).
   Google Scholar
• Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr. Oncol.14(Suppl. 1), S20–S40 (2007).
   PubMedGoogle Scholar
• Day R, Ganz PA, Costantino JP et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Clin. Oncol.17(9), 2659–2669 (1999).
   PubMed Web of Science ®Google Scholar
• Kwan KW, Chlebowski RT. Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin. Breast Cancer9(4), 219–224 (2009).
   PubMed Web of Science ®Google Scholar
• Menezes M, Pereira M, Hextall A. Predictors of female urinary incontinence at midlife and beyond. Maturitas65(2), 167–171 (2010).
   PubMedGoogle Scholar
• Barlow DH, Cardozo LD, Francis RM et al. Urogenital ageing and its effect on sexual health in older British women. Br. J. Obstet. Gynaecol.104(1), 87–91 (1997).
   PubMedGoogle Scholar
• Delmanto A, Nahas-Neto J, Nahas EA et al. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol.139(2), 187–192 (2008).
   PubMed Web of Science ®Google Scholar
• Jenkins MR, Sikon AL. Update on nonhormonal approaches to menopausal management. Cleve. Clin. J. Med.75(Suppl. 4), S17–S24 (2008).
   PubMedGoogle Scholar
• Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B. Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J. Natl Cancer Inst.87(18), 1372–1382 (1995).
   PubMed Web of Science ®Google Scholar
• Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women’s health-related quality of life and sexual functioning. J. Clin. Oncol.16(2), 501–514 (1998).
   PubMed Web of Science ®Google Scholar
• Lester JL, Bernhard LA. Urogenital atrophy in breast cancer survivors. Oncol. Nurs. Forum36(6), 693–698 (2009).
   PubMedGoogle Scholar
• Mortimer JE, Boucher L, Baty J et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J. Clin. Oncol.17(5), 1488–1492 (1999).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Bruzzi P, Rubagotti A, Nicolo GU, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology38(5), 281–285 (1981).
   PubMed Web of Science ®Google Scholar
• Ferrazzi E, Cartei G, Mattarazzo R, Fiorentino M. Oestrogen-like effect of tamoxifen on vaginal epithelium. Br. Med. J.1(6072), 1351–1352 (1977).
   PubMedGoogle Scholar
• Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T. Continuous combined hormone replacement therapy compared with tibolone. Obstet. Gynecol.93(2), 258–264 (1999).
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J. Clin. Oncol.21(4), 602–606 (2003).
   PubMed Web of Science ®Google Scholar
• Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J. Clin. Oncol.26(4), 556–562 (2008).
   PubMed Web of Science ®Google Scholar
• Mortimer JE. Managing the toxicities of the aromatase inhibitors. Curr. Opin. Obstet. Gynecol.22(1), 56–60 (2010).
   PubMedGoogle Scholar
• Yildirim B, Kaleli B, Duzcan E, Topuz O. The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas49(4), 334–337 (2004).
   PubMed Web of Science ®Google Scholar
• Abban G, Yildirim NB, Jetten AM. Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin D3. Eur. J. Histochem.52(2), 107–114 (2008).
   PubMedGoogle Scholar
• Bodnar LM, Krohn MA, Simhan HN. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. J. Nutr.139(6), 1157–1161 (2009).
   PubMed Web of Science ®Google Scholar
• Checa MA, Garrido A, Prat M et al. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. Maturitas52(1), 70–77 (2005).
   PubMed Web of Science ®Google Scholar
• Kaufert P, Boggs PP, Ettinger B, Woods NF, Utian WH. Women and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Menopause5(4), 197–202 (1998).
   PubMed Web of Science ®Google Scholar
• Kupferer EM, Dormire SL, Becker H. Complementary and alternative medicine use for vasomotor symptoms among women who have discontinued hormone therapy. J. Obstet. Gynecol. Neonatal Nurs.38(1), 50–59 (2009).
   PubMed Web of Science ®Google Scholar
• Kam IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause9(1), 72–78 (2002).
   PubMed Web of Science ®Google Scholar
• Rotem C, Kaplan B. Phyto-female complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol. Endocrinol.23(2), 117–122 (2007).
   PubMed Web of Science ®Google Scholar
• Ushiroyama T, Yoshida S, Tadaki K, Ikeda A, Ueki M. A pilot study of a Kampo formula, EH0202, with intriguing results for menopausal symptoms. J. Altern. Complement. Med.10(2), 397–399 (2004).
   PubMedGoogle Scholar
• Obi N, Chang-Claude J, Berger J et al. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case–control study. Cancer Epidemiol. Biomarkers Prev.18(8), 2207–2213 (2009).
   PubMed Web of Science ®Google Scholar
• Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr. J.7, 17 (2008).
   PubMed Web of Science ®Google Scholar
• Reiter E, Beck V, Medjakovic S, Mueller M, Jungbauer A. Comparison of hormonal activity of isoflavone-containing supplements used to treat menopausal complaints. Menopause16(5), 1049–1060 (2009).
   PubMed Web of Science ®Google Scholar
• Low Dog T. Menopause: a review of botanical dietary supplements. Am. J. Med.118(Suppl. 12B), 98–108 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms – a systematic review. Mol. Nutr. Food Res.53(9), 1084–1097 (2009).
   PubMed Web of Science ®Google Scholar
• Geller SE, Shulman LP, van Breemen RB et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause16(6), 1156–1166 (2009).
   PubMed Web of Science ®Google Scholar
• Cline JM, Franke AA, Register TC, Golden DL, Adams MR. Effects of dietary isoflavone aglycones on the reproductive tract of male and female mice. Toxicol. Pathol.32(1), 91–99 (2004).
   PubMedGoogle Scholar
• McClain MR, Wolz E, Davidovich A et al. Acute, subchronic and chronic safety studies with genistein in rats. Food Chem. Toxicol.44(1), 56–80 (2006).
   PubMed Web of Science ®Google Scholar
• Reed SD, Newton KM, LaCroix AZ et al. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause15(1), 51–58 (2008).
   PubMed Web of Science ®Google Scholar
• Shams T, Setia MS, Hemmings R et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern. Ther. Health Med.16(1), 36–44 (2010).
   PubMed Web of Science ®Google Scholar
• Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause16(5), 956–965 (2009).
   PubMed Web of Science ®Google Scholar
• Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause17(2), 426–440 (2010).
   PubMed Web of Science ®Google Scholar
• Newton KM, Reed SD, LaCroix AZ et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann. Intern. Med.145(12), 869–879 (2006).
   PubMed Web of Science ®Google Scholar
• Lipovac M, Chedraui P, Gruenhut C et al. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts. Maturitas65(3), 258–261 (2010).
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician–Gynecologists. Use of botanicals for management of menopausal symptoms. Obstet. Gynecol.97(Suppl. 6), 1–11 (2001).
   PubMedGoogle Scholar
• van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus (Chaste-Tree/Berry) in the treatment of menopause-related complaints. J. Altern. Complement. Med.15(8), 853–862 (2009).
   PubMed Web of Science ®Google Scholar
• van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause16(1), 156–163 (2009).
   PubMed Web of Science ®Google Scholar
• Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric4(2), 144–150 (2001).
   PubMedGoogle Scholar
• Albertazzi P. Non-estrogenic approaches for the treatment of climacteric symptoms. Climacteric10(Suppl. 2), 115–120 (2007).
   PubMed Web of Science ®Google Scholar
• Dickman JR, Koenig RT, Ji LL. American ginseng supplementation induces an oxidative stress in postmenopausal women. J. Am. Coll. Nutr.28(2), 219–228 (2009).
   PubMed Web of Science ®Google Scholar
• Israel D, Youngkin EQ. Herbal therapies for perimenopausal and menopausal complaints. Pharmacotherapy17(5), 970–984 (1997).
   PubMed Web of Science ®Google Scholar
• Chung MH, Suzuki S, Nishihara T, Hattori M. Estrogenic effects of a Kampo formula, Tokishakuyakusan, in parous ovariectomized rats. Biol. Pharm. Bull.31(6), 1145–1149 (2008).
   PubMed Web of Science ®Google Scholar
• Ushiroyama T, Yoshida S, Tadaki K, Ikeda A, Ueki M. Clinical efficacy of EH0202, a Kampo formula, on the health of middle-aged women. Am. J. Chin. Med.32(5), 755–770 (2004).
   PubMedGoogle Scholar
• Scheid V, Ward T, Cha WS, Watanabe K, Liao X. The treatment of menopausal symptoms by traditional East Asian medicines: review and perspectives. Maturitas66(2), 111–130 (2010).
   PubMed Web of Science ®Google Scholar
• Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. Maturitas66(4), 333–343 (2010).
   PubMed Web of Science ®Google Scholar
• Schonberg MA, Wee CC. Menopausal symptom management and prevention counseling after the Women’s Health Initiative among women seen in an internal medicine practice. J. Womens Health (Larchmt.)14(6), 507–514 (2005).
   PubMed Web of Science ®Google Scholar
• Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol.92(4 Pt 2), 722–727 (1998).
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging24(5), 361–379 (2007).
   PubMed Web of Science ®Google Scholar
• Galhardo CL, Soares JM Jr, Simoes RS et al. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin. Exp. Obstet. Gynecol.33(2), 85–89 (2006).
   PubMed Web of Science ®Google Scholar
• Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual. Life Outcomes3, 47 (2005).
   PubMedGoogle Scholar
• Gelfand MM, Moreau M, Ayotte NJ et al. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause10(1), 29–36 (2003).
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int. J. Fertil. Womens Med.44(6), 286–296 (1999).
   PubMed Web of Science ®Google Scholar
• Bennink HJ. Reprint of: Are all estrogens the same? Maturitas61(1–2), 195–201 (2008).
   PubMedGoogle Scholar
• Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women. J. Sex. Med.5(1), 132–138 (2008).
   PubMed Web of Science ®Google Scholar
• Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J. Clin. Endocrinol. Metab.93(12), 4567–4575 (2008).
   PubMed Web of Science ®Google Scholar
• Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause7(3), 156–161 (2000).
   PubMed Web of Science ®Google Scholar
• Fournier A. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. Menopause Int.16(1), 23–32 (2010).
   PubMedGoogle Scholar
• Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br. J. Obstet. Gynaecol.104(Suppl. 16), 4–13 (1997).
   PubMedGoogle Scholar
• Mattsson LA, Bohnet HG, Gredmark T et al. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. Obstet. Gynecol.94(1), 61–65 (1999).
   PubMed Web of Science ®Google Scholar
• Nachtigall LE. Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Am. J. Obstet. Gynecol.173(3 Pt 2), 993–997 (1995).
   PubMed Web of Science ®Google Scholar
• Sturdee DW. Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int. J. Clin. Pract.53(6), 468–472 (1999).
   PubMedGoogle Scholar
• Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric12(2), 91–105 (2009).
   PubMed Web of Science ®Google Scholar
• Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst. Rev.4, CD001405 (2009).
   Google Scholar
• Beral V, Banks E, Reeves G, Wallis M. Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet349(9058), 1103–1104 (1997).
   PubMedGoogle Scholar
• Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA288(3), 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Hulley S, Furberg C, Barrett-Connor E et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA288(1), 58–66 (2002).
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey MP, Hawkins MM et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet348(9033), 977–980 (1996).
   PubMed Web of Science ®Google Scholar
• Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet348(9033), 981–983 (1996).
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet348(9033), 983–987 (1996).
   PubMed Web of Science ®Google Scholar
• Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet. Gynecol.83(1), 5–11 (1994).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson, Garnet L et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA304(15), 1684–1692 (2010).
   PubMed Web of Science ®Google Scholar
• Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas65(3), 190–197 (2010).
   PubMed Web of Science ®Google Scholar
• Holmberg L, Anderson H. HABITS (Hormonal Replacement Therapy after Breast Cancer – Is It Safe?), a randomised comparison: trial stopped. Obstet. Gynecol.363(9407), 453–455 (2004).
   Google Scholar
• Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet. Gynecol.115(4), 839–855 (2010).
   PubMed Web of Science ®Google Scholar
• Grady D, Brown JS, Vittinghoff E et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet. Gynecol.97(1), 116–120 (2001).
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Cochrane BB, Nygaard IE et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA293(8), 935–948 (2005).
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause14(3 Pt 1), 355–369; quiz 370–351 (2007).
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause16(1), 30–36 (2009).
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch. Intern. Med.156(19), 2213–2217 (1996).
   PubMed Web of Science ®Google Scholar
• Krause M, Wheeler TL, Holly ER, Thomas SE. Systemic effects of vaginally administered estrogen therapy. Female Pelvic Med. Reconstruc. Surg.16, 188–195 (2010).
   PubMedGoogle Scholar
• Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N. Engl. J. Med.298(4), 195–197 (1978).
   PubMed Web of Science ®Google Scholar
• Dorr MB, Nelson AL, Mayer PR et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil. Steril.94(6), 2365–2368 (2010).
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Urogenital aging: solutions in clinical practice. Int. J. Gynaecol. Obstet.59(Suppl. 1), S35–S39 (1997).
   PubMedGoogle Scholar
• Hurst BS, Jones AI, Elliot M, Marshburn PB, Matthews ML. Absorption of vaginal estrogen cream during sexual intercourse: a prospective, randomized, controlled trial. J. Reprod. Med.53(1), 29–32 (2008).
   PubMedGoogle Scholar
• Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom. Med.49(4), 397–409 (1987).
   PubMed Web of Science ®Google Scholar
• Shulman LP. Androgens and menopause. Minerva Ginecol.61(6), 491–497 (2009).
   PubMedGoogle Scholar
• Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric11(3), 181–191 (2008).
   PubMed Web of Science ®Google Scholar
• Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas21(3), 227–236 (1995).
   PubMed Web of Science ®Google Scholar
• Tuiten A, Van Honk J, Koppeschaar H et al. Time course of effects of testosterone administration on sexual arousal in women. Arch. Gen. Psychiatry57(2), 149–153; discussion 155–156 (2000).
   PubMed Web of Science ®Google Scholar
• Sarrel P, Dobay B, Wiita B. Estrogen and estrogen–androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J. Reprod. Med.43(10), 847–856 (1998).
   PubMed Web of Science ®Google Scholar
• Labrie F, Belanger A, Belanger P et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J. Steroid Biochem. Mol. Biol.99(4–5), 182–188 (2006).
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Belanger A et al. Is dehydroepiandrosterone a hormone? J. Endocrinol.187(2), 169–196 (2005).
   PubMed Web of Science ®Google Scholar
• Buster JE. Transvaginal dehydroepiandrosterone: an unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: hormone precursor replacement therapy (HPRT). Menopause16(5), 858–859 (2009).
   PubMedGoogle Scholar
• Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J. Sex. Med.7(3), 1284–1290 (2010).
   PubMed Web of Science ®Google Scholar
• de Paula FJ, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas56(1), 69–77 (2007).
   PubMed Web of Science ®Google Scholar
• Foster GV, Zacur HA, Rock JA. Hot flashes in postmenopausal women ameliorated by danazol. Fertil. Steril.43(3), 401–404 (1985).
   PubMedGoogle Scholar
• Stearns V, Ullmer L, Lopez JF et al. Hot flushes. Lancet360(9348), 1851–1861 (2002).
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C et al. Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause16(5), 907–922 (2009).
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause16(5), 923–931 (2009).
   PubMed Web of Science ®Google Scholar
• Johannsson G, Burman P, Wiren L et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J. Clin. Endocrinol. Metab.87(5), 2046–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Spark RF. Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil. Steril.77(Suppl. 4), S19–S25 (2002).
   Web of Science ®Google Scholar
• Rubino S, Stomati M, Bersi C et al. Neuroendocrine effect of a short-term treatment with DHEA in postmenopausal women. Maturitas28(3), 251–257 (1998).
   PubMed Web of Science ®Google Scholar
• Stomati M, Monteleone P, Casarosa E et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol. Endocrinol.14(5), 342–363 (2000).
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J. Steroid Biochem. Mol. Biol.111(3–5), 178–194 (2008).
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL et al. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J. Steroid Biochem. Mol. Biol.110(1–2), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause16(5), 897–906 (2009).
   PubMed Web of Science ®Google Scholar
• Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecol. Endocrinol.26(11), 804–814 (2010).
   PubMed Web of Science ®Google Scholar
• Rymer J, Chapman MG, Fogelman I, Wilson PO. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas18(2), 127–133 (1994).
   PubMed Web of Science ®Google Scholar
• Nappi RE, Ferdeghini F, Sampaolo P et al. Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy. Maturitas55(3), 288–295 (2006).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD et al. The effects of tibolone in older postmenopausal women. N. Engl. J. Med.359(7), 697–708 (2008).
   PubMed Web of Science ®Google Scholar
• Nijland EA, Weijmar Schultz WC, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas58(2), 164–173 (2007).
   PubMed Web of Science ®Google Scholar
• Stovall DW. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. Curr. Opin. Investig. Drugs11(4), 464–471 (2010).
   PubMedGoogle Scholar
• Bai WP, Wang SY, Liu JL et al. [Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms]. Zhonghua Fu Chan Ke Za Zhi44(8), 597–600 (2009).
   PubMedGoogle Scholar
• de Vries CS, Bromley SE, Thomas H, Farmer RD. Tibolone and endometrial cancer: a cohort and nested case–control study in the UK. Drug Saf.28(3), 241–249 (2005).
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet365(9470), 1543–1551 (2005).
   PubMed Web of Science ®Google Scholar
• Sites CK. Bioidentical hormones for menopausal therapy. Womens Health (Lond. Engl.)4(2), 163–171 (2008).
   PubMedGoogle Scholar
• Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J. Womens Health (Larchmt.)16(5), 600–631 (2007).
   PubMed Web of Science ®Google Scholar
• Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet. Gynecol. Surv.63(3), 163–181 (2008).
   PubMed Web of Science ®Google Scholar
• Nath A, Sitruk-Ware R. Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric12(3), 188–205 (2009).
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause17(3), 642–653 (2010).
   PubMed Web of Science ®Google Scholar
• Wang XN, Simmons HA, Salatto CT, Cosgrove PG, Thompson DD. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor β and androgen receptor in rats. Menopause13(4), 609–620 (2006).
   PubMed Web of Science ®Google Scholar
• Gennari L. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opin. Pharmacother.10(13), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Gass M, Bachmann GM, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM), improves dyspareunia in postmenopausal women with vaginal atrophy (VA). Menopause12, 238 (2005).
   Google Scholar
• Gass M, Bachnamm G, Moffett A, Symons J. Clinical signs of vaginal atrophy are improved by the SERM, lasofoxifene. Menopause11, 670 (2004).
   Google Scholar
• Simon GM, Kagan R, Spino C, Nemmeth MA. Lasofoxifene effectively treats dyspareunia in postmenopausal women with vaginal atrophy. Obstet. Gynecol.105, 102S (2005).
   Google Scholar
• Bolognese MA. SERMs and SERMs with estrogen for postmenopausal osteoporosis. Rev. Endocr. Metab. Disord.11(4), 253–259 (2010).
   PubMedGoogle Scholar
• Gennari L. Lasofoxifene (Pfizer). Curr. Opin. Invest. Drugs6(10), 1067–1078 (2005).
   PubMedGoogle Scholar
• Pickar JH, Macneil T, Ohleth K. SERMs: progress and future perspectives. Maturitas67(2), 129–138 (2010).
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology146(9), 3999–4008 (2005).
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology149(12), 6084–6091 (2008).
   PubMed Web of Science ®Google Scholar
• Ronkin S, Northington R, Baracat E et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet. Gynecol.105(6), 1397–1404 (2005).
   PubMed Web of Science ®Google Scholar
• Pickar JH. The endometrium-from estrogens alone to TSECs. Climacteric12(6), 463–477 (2009).
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo-and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause17(2), 281–289 (2010).
   PubMed Web of Science ®Google Scholar
• Vardy MD, Lindsay R, Scotti RJ et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am. J. Obstet. Gynecol.189(1), 81–88 (2003).
   PubMed Web of Science ®Google Scholar
• Zeyneloglu HB, Oktem M, Haberal NA, Esinler I, Kuscu E. The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. Fertil. Steril.88(2), 530–532 (2007).
   PubMedGoogle Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295(23), 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Parsons A, Merritt D, Rosen A et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet. Gynecol.101(2), 346–352 (2003).
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Shifren JL, La Valleur J et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause10(1), 45–52 (2003).
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, Nuti R. Ospemifene use in postmenopausal women. Expert Opin. Investig. Drugs18(6), 839–849 (2009).
   PubMed Web of Science ®Google Scholar
• Qu Q, Zheng H, Dahllund J et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology141(2), 809–820 (2000).
   PubMed Web of Science ®Google Scholar
• Gennari L. Ospemifene hormos. Curr. Opin. Investig. Drugs5(4), 448–455 (2004).
   PubMedGoogle Scholar
• Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal Phase 3 study. Menopause17(3), 480–486 (2010).
   PubMed Web of Science ®Google Scholar